company background image
NLTX

Neoleukin Therapeutics NasdaqGM:NLTX Stock Report

Last Price

US$0.67

Market Cap

US$28.4m

7D

-1.5%

1Y

-90.3%

Updated

03 Oct, 2022

Data

Company Financials +
NLTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NLTX Stock Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.

Neoleukin Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neoleukin Therapeutics
Historical stock prices
Current Share PriceUS$0.67
52 Week HighUS$8.01
52 Week LowUS$0.62
Beta1.06
1 Month Change-33.91%
3 Month Change-33.91%
1 Year Change-90.27%
3 Year Change-76.66%
5 Year Change-95.23%
Change since IPO-94.41%

Recent News & Updates

Jun 03
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

NLTXUS BiotechsUS Market
7D-1.5%0.4%-2.5%
1Y-90.3%-25.6%-23.2%

Return vs Industry: NLTX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: NLTX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is NLTX's price volatile compared to industry and market?
NLTX volatility
NLTX Average Weekly Movement11.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NLTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NLTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200379John Drachmanhttps://www.neoleukin.com

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019.

Neoleukin Therapeutics, Inc. Fundamentals Summary

How do Neoleukin Therapeutics's earnings and revenue compare to its market cap?
NLTX fundamental statistics
Market CapUS$28.42m
Earnings (TTM)-US$61.65m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NLTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$61.65m
Earnings-US$61.65m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NLTX perform over the long term?

See historical performance and comparison